Thidathip Wongsurawat is currently the Group Leader of Siriraj’s Long-read Lab (Si-LoL) in the Faculty of Medicine at Siriraj Hospital, Mahidol University. Thidathip's research interest focuses on utilizing nanopore sequencing technology in cancer research with the primary goal of translating genomic data and novel ideas into clinical reality. Currently, she works closely with a multi-disciplinary team of scientists and clinicians on a nanopore-based project to develop a cutting-edge method for cancer diagnosis and treatment decisions.

The 2021 WHO Classification of Tumors of the Central Nervous System adopted CDKN2A/B deletion marker into the revised grading criteria of IDH-mutant astrocytoma. The CDKN2A/B deletion in IDH-mutant astrocytoma was identified as independent molecular markers of the worst clinical outcomes. Currently, there is no standard assay to assess CDKN2A/B deletion, and current tests, such as fluorescence in situ hybridization (FISH) and array-based platforms, require technical expertise and may not be readily available in routine laboratories. Here, we demonstrated the potential of the nanopore-based copy number variation approach to identify deletions of CDKN2A/B for glioma diagnosis and grading within four hours.